Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

David Wyles

Concepts (239)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
58
2025
709
11.530
 Why?
Hepatitis C, Chronic
31
2025
156
8.790
 Why?
Hepacivirus
46
2024
237
7.910
 Why?
Hepatitis C
27
2025
235
7.690
 Why?
Benzimidazoles
16
2020
158
4.410
 Why?
Drug Resistance, Viral
17
2018
110
3.310
 Why?
Coinfection
15
2020
133
3.160
 Why?
HIV Infections
28
2022
2744
3.140
 Why?
Ribavirin
15
2020
92
2.430
 Why?
Sofosbuvir
16
2022
57
2.360
 Why?
Quinoxalines
7
2019
64
2.340
 Why?
Sulfonamides
13
2020
494
2.330
 Why?
Fluorenes
7
2020
39
2.320
 Why?
Liver Cirrhosis
8
2020
278
2.270
 Why?
Viral Nonstructural Proteins
9
2018
58
2.020
 Why?
Drug Therapy, Combination
26
2020
1024
1.890
 Why?
Uridine Monophosphate
5
2016
15
1.750
 Why?
Carbamates
9
2020
45
1.520
 Why?
Anti-Retroviral Agents
5
2019
230
1.490
 Why?
Protease Inhibitors
10
2020
104
1.430
 Why?
Hepatitis B, Chronic
3
2019
18
1.400
 Why?
Proline
11
2020
79
1.300
 Why?
Pyrrolidines
9
2019
65
1.250
 Why?
Congresses as Topic
3
2021
217
1.220
 Why?
Hepatitis, Viral, Human
3
2021
26
1.190
 Why?
Genotype
19
2022
1836
1.020
 Why?
Cyclopropanes
11
2020
88
1.010
 Why?
Drug Users
2
2024
44
1.000
 Why?
Sustained Virologic Response
10
2020
35
0.950
 Why?
Lactams, Macrocyclic
10
2020
49
0.940
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
19
0.830
 Why?
HIV-1
8
2020
841
0.810
 Why?
Virus Replication
7
2012
449
0.770
 Why?
Disease Eradication
1
2020
4
0.720
 Why?
Organophosphonates
4
2011
91
0.700
 Why?
Homosexuality, Male
2
2021
180
0.700
 Why?
Anti-HIV Agents
6
2020
744
0.680
 Why?
Humans
75
2025
129705
0.670
 Why?
Valine
7
2020
78
0.660
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.570
 Why?
Imidazoles
2
2015
224
0.560
 Why?
Ritonavir
6
2020
73
0.550
 Why?
Darunavir
1
2017
17
0.550
 Why?
Treatment Failure
5
2019
347
0.540
 Why?
Aminoisobutyric Acids
5
2019
7
0.540
 Why?
Uracil
5
2020
29
0.520
 Why?
Treatment Outcome
18
2023
10299
0.510
 Why?
Leucine
5
2019
106
0.510
 Why?
Antiretroviral Therapy, Highly Active
3
2015
269
0.510
 Why?
Anilides
5
2020
72
0.500
 Why?
Middle Aged
30
2025
31103
0.500
 Why?
Education, Medical, Continuing
1
2016
126
0.480
 Why?
Male
39
2025
63544
0.480
 Why?
Biomedical Research
1
2021
656
0.470
 Why?
Adenine
4
2020
247
0.460
 Why?
RNA, Viral
7
2015
622
0.460
 Why?
Oligopeptides
2
2013
256
0.450
 Why?
Pyridazines
1
2014
48
0.450
 Why?
Viral Load
7
2020
449
0.450
 Why?
2-Naphthylamine
5
2020
7
0.440
 Why?
Macrocyclic Compounds
3
2019
10
0.430
 Why?
Adult
29
2025
35595
0.420
 Why?
Female
37
2025
68561
0.420
 Why?
Purines
1
2014
170
0.420
 Why?
Quinolines
1
2014
149
0.420
 Why?
Replicon
3
2009
14
0.410
 Why?
Liver
1
2021
1848
0.400
 Why?
Disease Management
1
2016
596
0.390
 Why?
Scavenger Receptors, Class B
1
2012
10
0.390
 Why?
Aged
17
2024
22113
0.370
 Why?
Retreatment
2
2021
69
0.350
 Why?
Drug Synergism
3
2008
354
0.340
 Why?
Acquired Immunodeficiency Syndrome
2
2020
227
0.310
 Why?
Dideoxynucleosides
2
2005
20
0.300
 Why?
Liver Diseases
2
2016
290
0.300
 Why?
Interferon-alpha
4
2013
191
0.290
 Why?
Cytokines
1
2015
2008
0.280
 Why?
Amino Acid Substitution
2
2018
281
0.270
 Why?
Global Health
2
2020
333
0.270
 Why?
Cytosine
2
2009
46
0.270
 Why?
Hepatitis B virus
2
2019
35
0.240
 Why?
Mass Screening
3
2023
1130
0.240
 Why?
HIV
2
2019
224
0.240
 Why?
Herpes Simplex
1
2005
94
0.230
 Why?
Hepatitis
1
2004
49
0.230
 Why?
Alanine
2
2021
134
0.220
 Why?
Prevalence
3
2019
2557
0.210
 Why?
Interferons
2
2015
187
0.210
 Why?
Young Adult
10
2019
12363
0.200
 Why?
Hospitals
2
2024
635
0.200
 Why?
Mutation, Missense
3
2014
319
0.200
 Why?
Interferon beta-1a
1
2021
12
0.190
 Why?
Hepatitis A
1
2021
26
0.180
 Why?
Adenosine Monophosphate
1
2021
62
0.180
 Why?
Tenofovir
2
2020
225
0.180
 Why?
Hepatitis B
1
2021
61
0.180
 Why?
World Health Organization
1
2020
109
0.170
 Why?
Disease Progression
2
2019
2612
0.170
 Why?
Data Interpretation, Statistical
2
2018
338
0.170
 Why?
Polyethylene Glycols
2
2015
598
0.160
 Why?
United States
10
2025
14078
0.160
 Why?
Ribosomes
2
2010
162
0.150
 Why?
Esters
2
2009
74
0.150
 Why?
CD4 Lymphocyte Count
2
2017
269
0.150
 Why?
Immunologic Factors
1
2020
230
0.150
 Why?
Nucleic Acid Conformation
4
2014
706
0.140
 Why?
Hospitalization
2
2024
2091
0.140
 Why?
Alanine Transaminase
1
2018
149
0.140
 Why?
DNA, Viral
1
2019
381
0.140
 Why?
Genes, Viral
1
2016
94
0.140
 Why?
DNA Mutational Analysis
1
2018
391
0.130
 Why?
Mutation
2
2018
3674
0.130
 Why?
Molecular Structure
2
2008
469
0.130
 Why?
High-Throughput Nucleotide Sequencing
2
2016
484
0.130
 Why?
Patient Compliance
1
2020
566
0.130
 Why?
Survival Analysis
1
2019
1297
0.130
 Why?
Adolescent
5
2022
20355
0.130
 Why?
Dose-Response Relationship, Drug
2
2017
1969
0.120
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
19
0.120
 Why?
Opiate Substitution Treatment
1
2016
140
0.120
 Why?
AIDS-Related Opportunistic Infections
1
2015
126
0.120
 Why?
Chemokines
1
2015
230
0.110
 Why?
Chemokine CXCL10
1
2014
33
0.110
 Why?
Drug Interactions
1
2015
371
0.110
 Why?
Phenylenediamines
1
2013
9
0.110
 Why?
Viral Proteins
2
2014
330
0.110
 Why?
Fibrosis
1
2016
521
0.110
 Why?
Prognosis
2
2019
3801
0.110
 Why?
Quality of Life
1
2025
2712
0.100
 Why?
Microbial Sensitivity Tests
2
2012
351
0.100
 Why?
Drug Combinations
3
2019
327
0.100
 Why?
Drug Discovery
1
2013
131
0.100
 Why?
Administration, Oral
1
2014
790
0.100
 Why?
Mental Disorders
1
2020
1025
0.090
 Why?
Cohort Studies
5
2024
5410
0.090
 Why?
Case-Control Studies
2
2017
3363
0.090
 Why?
Telemedicine
1
2020
792
0.090
 Why?
Models, Molecular
3
2012
1480
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
259
0.090
 Why?
Prodrugs
1
2011
49
0.090
 Why?
Nucleosides
1
2010
25
0.090
 Why?
Japan
2
2021
102
0.090
 Why?
Riboswitch
1
2012
68
0.090
 Why?
Cell Line, Tumor
2
2008
3106
0.080
 Why?
Prospective Studies
4
2023
7130
0.080
 Why?
Drug Administration Schedule
3
2017
763
0.080
 Why?
Risk Assessment
1
2019
3297
0.080
 Why?
Drug Design
1
2010
157
0.080
 Why?
Biomarkers
1
2020
3893
0.080
 Why?
Cell Line
2
2012
2768
0.080
 Why?
Piperidines
1
2010
186
0.080
 Why?
Body Mass Index
1
2017
2246
0.080
 Why?
Phenylthiourea
1
2008
5
0.080
 Why?
Practice Guidelines as Topic
1
2016
1529
0.080
 Why?
Immunity, Innate
1
2014
806
0.070
 Why?
Plasmids
1
2009
359
0.070
 Why?
Structure-Activity Relationship
1
2009
539
0.070
 Why?
Inhibitory Concentration 50
1
2006
83
0.070
 Why?
Luciferases
1
2006
148
0.070
 Why?
Genes, Reporter
1
2006
269
0.060
 Why?
Thailand
1
2025
16
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Indinavir
1
2004
7
0.060
 Why?
Simplexvirus
1
2005
83
0.060
 Why?
Nelfinavir
1
2004
8
0.060
 Why?
Drug Labeling
1
2005
42
0.060
 Why?
Uganda
1
2025
80
0.060
 Why?
Brazil
1
2025
102
0.060
 Why?
Nevirapine
1
2004
16
0.060
 Why?
Oxazines
1
2004
26
0.060
 Why?
Pandemics
2
2024
1526
0.060
 Why?
Benzoxazines
1
2004
31
0.060
 Why?
Lopinavir
1
2004
31
0.060
 Why?
Alkynes
1
2004
53
0.060
 Why?
Zidovudine
1
2004
78
0.060
 Why?
Time Factors
1
2015
6593
0.060
 Why?
Pregnancy
1
2017
6273
0.060
 Why?
Liver Function Tests
1
2004
116
0.060
 Why?
Reverse Transcriptase Inhibitors
1
2004
82
0.060
 Why?
Transfection
1
2006
904
0.060
 Why?
Carcinoma, Hepatocellular
1
2006
267
0.060
 Why?
South Africa
1
2025
199
0.060
 Why?
Bone Marrow Transplantation
1
2005
267
0.060
 Why?
Pyrimidinones
1
2004
102
0.060
 Why?
Recombinant Fusion Proteins
1
2006
640
0.060
 Why?
Double-Blind Method
2
2021
1871
0.050
 Why?
Polyphosphates
1
2022
36
0.050
 Why?
Republic of Korea
1
2021
28
0.050
 Why?
Singapore
1
2021
20
0.050
 Why?
Dried Blood Spot Testing
1
2022
84
0.050
 Why?
Liver Neoplasms
1
2006
637
0.050
 Why?
Retrospective Studies
5
2019
14669
0.050
 Why?
Mexico
1
2021
188
0.050
 Why?
Protein Biosynthesis
2
2014
409
0.050
 Why?
Emergency Service, Hospital
2
2023
2044
0.050
 Why?
Raltegravir Potassium
1
2019
17
0.040
 Why?
Intensive Care Units
1
2024
738
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
73
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
91
0.040
 Why?
Drug Resistance, Multiple, Viral
1
2017
11
0.040
 Why?
Longitudinal Studies
1
2024
2670
0.030
 Why?
Kinetics
1
2020
1620
0.030
 Why?
Oxygen
1
2021
921
0.030
 Why?
Medicaid
1
2020
447
0.030
 Why?
Program Evaluation
1
2020
880
0.030
 Why?
Incidence
2
2013
2658
0.030
 Why?
RNA
1
2022
877
0.030
 Why?
Cell-Free System
1
2014
48
0.030
 Why?
Hepatitis C Antibodies
1
2014
10
0.030
 Why?
Spain
1
2014
38
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
828
0.030
 Why?
Polymorphism, Genetic
1
2017
643
0.030
 Why?
Aged, 80 and over
2
2019
7074
0.030
 Why?
Patient Acceptance of Health Care
1
2020
776
0.030
 Why?
Patient Reported Outcome Measures
1
2017
359
0.030
 Why?
Risk Factors
2
2020
9832
0.030
 Why?
Withholding Treatment
1
2013
69
0.030
 Why?
Patient Care
1
2014
110
0.030
 Why?
Early Diagnosis
1
2014
235
0.030
 Why?
Plasma
1
2014
206
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2012
175
0.020
 Why?
Virus Internalization
1
2010
43
0.020
 Why?
Ligands
1
2012
615
0.020
 Why?
Pilot Projects
1
2015
1567
0.020
 Why?
Recombinant Proteins
1
2013
1306
0.020
 Why?
Magnesium
1
2009
152
0.020
 Why?
Lamivudine
1
2009
61
0.020
 Why?
Genome, Viral
1
2009
131
0.020
 Why?
Referral and Consultation
1
2014
731
0.020
 Why?
Logistic Models
1
2013
1980
0.020
 Why?
Phenotype
1
2014
3063
0.020
 Why?
Base Sequence
1
2009
2161
0.020
 Why?
Severity of Illness Index
1
2013
2783
0.020
 Why?
Randomized Controlled Trials as Topic
1
2011
1379
0.010
 Why?
Mice, Transgenic
1
2009
2075
0.010
 Why?
Animals
2
2018
34733
0.010
 Why?
Substance-Related Disorders
1
2011
1023
0.010
 Why?
Signal Transduction
1
2009
4863
0.010
 Why?
Mice
1
2009
16585
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (239) concept(s)
_
Co-Authors Expand Description
See all (17) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)